Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis

BACKGROUND: There are conflicting reports on the results of several of the latest clinical trials related to the use of baricitinib in the management of COVID-19 patients. The aim of the current systematic review and meta-analysis was to evaluate the efficacy of baricitinib in COVID-19 patients. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Manoharan, Sivananthan, Ying, Lee Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477792/
https://www.ncbi.nlm.nih.gov/pubmed/36150282
http://dx.doi.org/10.1016/j.rmed.2022.106986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477792/
https://www.ncbi.nlm.nih.gov/pubmed/36150282
http://dx.doi.org/10.1016/j.rmed.2022.106986

Ejemplares similares